Intermittent Androgen Suppression Therapy for Prostate Cancer

https://doi.org/10.58571/CNCA.AMCA.2025.028

Resumen: This paper analyzes the dynamics of prostate cancer under two primary androgen deprivation therapies: Continuous Androgen Suppression and Intermittent Androgen Suppression. Prostate cancer, a leading cause of male cancer mortality, often develops resistance to androgen deprivation therapies due to the emergence of androgen-independent tumor cells. We use a clinically validated mathematical model which captures interaction between androgen levels in the body, androgen-dependent tumor cells, and androgen-independent tumor cells. Numerical simulations reveal that Intermittent Androgen Suppression therapy delays tumor recurrence compared to Continuous Androgen Suppression therapy by modulating androgen levels through threshold-based control of prostate-specific antigen. Our results highlight the critical role of proliferation dynamics in androgen-independent cells, as well as the importance of therapeutic strategies in the containment of resistance to androgen suppression therapy for prostate cancer.

¿Cómo citar?

Ramirez, F., Saldivar, B. & Hernández-Gómez, A. (2025). Intermittent Androgen Suppression Therapy for Prostate Cancer. Memorias del Congreso Nacional de Control Automático 2025, pp. 161-166. https://doi.org/10.58571/CNCA.AMCA.2025.028

Palabras clave

Prostate cancer, continuous androgen suppression, intermittent androgen suppression, mathematical model.

• Berges, R.R., Vukanovic, J., Epstein, J.I., et al. (1995). Implication of cell kinetic changes during the progression of human prostatic cancer. Clinical Cancer Research, 1, 473–480.
• Bladou, F. et al. (1996). Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. International Journal of Cancer.
• Feldman, B.J. and Feldman, D. (2001). The development of androgen-independent prostate cancer. Nature Reviews Cancer, 1(1), 34–45.
• Hirata, Y., Aihara, K., and Shimada, T. (2010). Development of a mathematical model for intermittent androgen suppression. Prostate Cancer and Prostatic Diseases, 13, 353–359.
• Huggins, C. and Hodges, C.V. (1941). Studies on prostatic cancer: I. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research, 1, 293–297.
• Hussain, M., Tangen, C.M., Berry, D.L., et al. (2012). Intermittent versus continuous androgen deprivation in prostate cancer. New England Journal of Medicine, 367(2), 118–126. doi:10.1056/NEJMoa1110032.
• Ideta, A., Aihara, K., and Shimada, T. (2008). Mathematical model of intermittent androgen suppression for prostate cancer. Journal of Theoretical Biology, 251, 731–744.
• National Cancer Institute (2023). Prostate cancer treatment (pdq®)–patient version. URL https://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq.
• Organización Mundial de la Salud (2022). Cáncer de próstata: Datos y cifras. URL https://gco.iarc.who.int/media/globocan/factsheets/cancers/27-prostate-fact-sheet.pdf.
• Swanson, K.R., True, L.D., Lin, D.W., and Buhler, K.R. (2001). A quantitative model for the dynamics of serum prostate-specific antigen as a marker for cancerous growth: An explanation for a medical anomaly. American Journal of Pathology, 158(6), 2195–2199.